Comparison of gadolinium-BOPTA and ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient

Investigative Radiology

Volumn 41, Issue 3, 2006, Pages 264-271

  Wersebe, Annika ^a   Wiskirchen, Jakub ^a   Decker, Udo ^a   Schick, Fritz ^a   Dietz, Klaus ^b   Müller Schimpfle, Markus ^c   Claussen, Claus D ^a   Pereira, Philippe L ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Eye Hospital   (Germany)

Author keywords

Comperative studies; Liver MRI; MR imaging; Superparamagnetic iron oxide (SPIO); Volumetric interpolated breath hold examination (VIBE)

Indexed keywords

FERUCARBOTRAN; GADOBENIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IRON; MEGLUMINE; ORGANOMETALLIC COMPOUND; OXIDE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; AORTA; ARTERIAL CIRCULATION; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; IMAGE ENHANCEMENT; LIVER INJURY; LIVER PARENCHYMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PARAMETERS OF MEASUREMENT AND ANALYSIS; PORTAL VEIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL DETECTION; SPLEEN; STATISTICAL ANALYSIS; THREE DIMENSIONAL IMAGING; VENOUS CIRCULATION; COMPARATIVE STUDY; FEMALE; LIVER DISEASE; MALE; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; IRON; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OXIDES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33745889954     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000188359.72928.0f     Document Type: Article

References (33)

1. Kehagias DT, Gouliamos AD, Smyrniotis V, et al. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SHU 555 A). J Magn Reson Imaging. 2001;14:595-601.
2. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319-2331.
3. Mori K, Scheidler J, Helmberger T, et al. Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferucarbotranmoxides-enhanced MR imaging. AJR Am J Roentgenol. 2002;179:1045-1051.
4. Arbab AS, Ichikawa T, Sou H, et al. Ferucarbotranmoxides-enhanced double-echo T2-weighted MR imaging in differentiating metastases from nonsolid benign lesions of the liver. Radiology. 2002;225:151-158.
5. del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferucarbotranmoxides-enhanced MR imaging examinations. Radiology. 2002;225:766-772.
6. Ba-Ssalamah A, Heinz-Peer G, Schima W, et al. Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging. 2000;11:665-762.
7. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-158.
8. Vogl TJ, Schwarz W, Blume S, et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol. 2003;13:262-272.
9. Lencioni R, Della Pina C, Bruix J, et al. Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. Dig Dis Sci. 2005;50:533-537.
10. Kim YK, Kim CS, Kwak HS, et al. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced MR imaging. J Magn Reson Imaging. 2004;20:826-837.
11. Hamm B, Thoeni R, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material enhanced MR imaging. Radiology. 1994;190:417-423.
12. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology. 1997;202:677-682.
13. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998;33:798-809.
14. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology. 2000;215:727-736.
15. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol. 2000;175:1111-1120.
16. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol. 2001;36:632-641.
17. Reimer P, Muller M, Marx C, et al. T1 effects of a bolus-injectable superparamagnetic iron oxide, SHU 555 A: dependence on field strength and plasma concentration - preliminary clinical experience with dynamic T1-weighted MR imaging. Radiology. 1998;209:831-836.
18. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266-1276.
19. Sahani D, Saini S, Sharma R, et al. Dynamic T1-weighted ferucarbotranmoxide enhanced MRI for imaging liver hemangiomas: preliminary observations. Abdom Imaging. 2001;26:166-170.
20. Zheng WW, Zhou KR, Chen ZW, et al. Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol. 2002;8:82-86.
21. Takahama K, Amano Y, Hayashi H, et al. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferucarbotranmoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging. Abdom Imaging. 2003;28:525-530.
22. Stroszczynski C, Gaffke G, Gretschel S, et al. Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis. Rofo. 2003;175:1368-1375.
23. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology. 1999;212:876-884.
24. Heim P, Steiner P, Schoder V, et al. Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI. Rofo. 2003;175:1376-1383.
25. Vogt FM, Antoch G, Hunold P, et al. Parallel acquisition techniques for accelerated volumetric interpolated breath-hold examination magnetic resonance imaging of the upper abdomen: assessment of image quality and lesion conspicuity. J Magn Reson Imaging. 2005;21:376-382.
26. Kwak HS, Lee JM, Kim YK, et al. Detection of hepatocellular carcinoma: comparison of ferucarbotranmoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol. 2005;15:140-147.
27. Vogl TJ, Hammerstingl R, Schwarz W, et al. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol. 1996;31:696-708.
28. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94.
29. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221.
30. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
31. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-BOPTA-DTPA in MR imaging of rat liver. Radiology. 1990;176:61-64.
32. Planchamp C, Montet X, Frossard JL, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol. 2005;40:187-194.
33. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging. 1994;4:659-668.